Citations (110)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (31)
Brian Godman, Mainul Haque, Santosh Kumar, Salequl Islam, Jaykaran Charan, Farhana Akter, Amanj Kurdi, Eleonora Allocati, Muhammed Abu Bakar, Sagir Abdur Rahim, Nusrat Sultana, Farzana Deeba, M. A. Halim Khan, A. B. M Muksudul Alam, Iffat Jahan, Zubair Mahmood Kamal, Humaira Hasin, Munzur-E-Murshid, Shamsun Nahar, Monami Haque, Siddhartha Dutta, Jha Pallavi Abhayanand, Rimple Jeet Kaur, Jitendra Acharya, Takuma Sugahara, Hye-Young Kwon, SeungJin Bae, Karen Koh Pek Khuan, Tanveer Ahmed Khan, Shahzad Hussain, Zikria Saleem, Alice Pisana, Janney Wale & Mihajlo Jakovljevic. (2021) Current utilization patterns for long-acting insulin analogues including biosimilars among selected Asian countries and the implications for the future. Current Medical Research and Opinion 37:9, pages 1529-1545.
Read now
Read now
James Weatherall, Jacob Simonsen & Brian L. Odlaug. (2020) The relative efficiency of schizophrenia health care systems: an international comparison using data envelopment analysis. Journal of Medical Economics 23:10, pages 1186-1192.
Read now
Read now
Kyriakos Souliotis, Christina Golna, Chara Kani & Sophia Markantonis. (2019) Exploring knowledge and perceptions on generic drugs of final year pharmacy school students in Greece. Expert Review of Pharmacoeconomics & Outcomes Research 19:5, pages 569-574.
Read now
Read now
Holly McCabe, Brian Godman, Amanj Kurdi, Katie Johnston, Sean MacBride-Stewart, Janey Lennon, Simon Hurding, Marion Bennie & Alec Morton. (2019) Prescribing trends of inhaler treatments for asthma and chronic obstructive pulmonary disease within a resource-constrained environment in the Scottish national health service: findings and implications. Expert Review of Respiratory Medicine 13:7, pages 679-689.
Read now
Read now
Joseph O. Fadare, Olayinka Ogunleye, Reginald Obiako, Samuel Orubu, Okezie Enwere, Adetutu A. Ajemigbitse, Johanna C. Meyer, Ehijie Enato, Amos Massele, Brian Godman & Lars L. Gustafsson. (2018) Drug and therapeutics committees in Nigeria: evaluation of scope and functionality. Expert Review of Clinical Pharmacology 11:12, pages 1255-1262.
Read now
Read now
Ines Potočnjak, Robert Likić, Vesna Degoricija, Eric Nham & Björn Wettermark. (2018) The benzodiazepine nation of Croatia: an observational, comparative study of psychotropic drug utilization between Croatia and Sweden 2014–2015. Expert Review of Pharmacoeconomics & Outcomes Research 18:6, pages 641-646.
Read now
Read now
Axel Leporowski, Brian Godman, Amanj Kurdi, Sean MacBride-Stewart, Margaret Ryan, Simon Hurding, Renata CRM Do Nascimento, Marion Bennie & Alec Morton. (2018) Ongoing activities to optimize the quality and efficiency of lipid-lowering agents in the Scottish national health service: influence and implications. Expert Review of Pharmacoeconomics & Outcomes Research 18:6, pages 655-666.
Read now
Read now
Moliehi Matlala, Andries GS Gous, Brian Godman & Johanna C Meyer. (2017) Structure and activities of pharmacy and therapeutics committees among public hospitals in South Africa; findings and implications. Expert Review of Clinical Pharmacology 10:11, pages 1273-1280.
Read now
Read now
Joseph O Fadare, Adekunle O. Adeoti, Olufemi O. Desalu, Okezie O. Enwere, Aliyu M. Makusidi, Olayinka Ogunleye, Taofiki A. Sunmonu, Ilse Truter, Onyinye O Akunne & Brian Godman. (2016) The prescribing of generic medicines in Nigeria: knowledge, perceptions and attitudes of physicians. Expert Review of Pharmacoeconomics & Outcomes Research 16:5, pages 639-650.
Read now
Read now
L. P. Thai, J. R. Moss, B. Godman & A. I. Vitry. (2016) Cost driver analysis of statin expenditure on Australia’s Pharmaceutical Benefits Scheme. Expert Review of Pharmacoeconomics & Outcomes Research 16:3, pages 419-433.
Read now
Read now
Govin Permanand & Hanne Bak Pedersen. (2015) Managing new premium-priced medicines in Europe. Journal of Pharmaceutical Policy and Practice 8:sup1.
Read now
Read now
Hye-Young Kwon, Hyungmin Kim, Brian Godman & Michael R Reich. (2015) The impact of South Korea’s new drug-pricing policy on market competition among off-patent drugs. Expert Review of Pharmacoeconomics & Outcomes Research 15:6, pages 1007-1014.
Read now
Read now
Rabiatul Salmi Md Rezal, Mohamed Azmi Hassali, Alian A Alrasheedy, Fahad Saleem, Faridah Aryani Md Yusof & Brian Godman. (2015) Physicians’ knowledge, perceptions and behaviour towards antibiotic prescribing: a systematic review of the literature. Expert Review of Anti-infective Therapy 13:5, pages 665-680.
Read now
Read now
Brian Godman, Iain Bishop, Stephen M Campbell, Rickard E Malmström & Ilse Truter. (2015) Quality and efficiency of statin prescribing across countries with a special focus on South Africa; findings and future implications. Expert Review of Pharmacoeconomics & Outcomes Research 15:2, pages 323-330.
Read now
Read now
Jurij Fürst, Milan Čižman, Jana Mrak, Damjan Kos, Stephen Campbell, Samuel Coenen, Lars L Gustafsson, Luka Fürst & Brian Godman. (2015) The influence of a sustained multifaceted approach to improve antibiotic prescribing in Slovenia during the past decade: findings and implications. Expert Review of Anti-infective Therapy 13:2, pages 279-289.
Read now
Read now
Brian Godman, Rickard E Malmström, Eduardo Diogene, Andy Gray, Sisira Jayathissa, Angela Timoney, Francisco Acurcio, Ali Alkan, Anna Brzezinska, Anna Bucsics, Stephen M Campbell, Jadwiga Czeczot, Winnie de Bruyn, Irene Eriksson, Faridah Aryani Md Yusof, Alexander E Finlayson, Jurij Fürst, Kristina Garuoliene, Augusto Guerra Júnior, Jolanta Gulbinovič, Saira Jan, Roberta Joppi, Marija Kalaba, Einar Magnisson, Laura McCullagh, Kaisa Miikkulainen, Gabriela Ofierska-Sujkowska, Hanne Bak Pedersen, Gisbert Selke, Catherine Sermet, Susan Spillane, Azuwana Supian, Ilse Truter, Vera Vlahović-Palčevski, Low Ee Vien, Elif H Vural, Janet Wale, Magdałene Władysiuk, Wenjie Zeng & Lars L Gustafsson. (2015) Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?. Expert Review of Clinical Pharmacology 8:1, pages 77-94.
Read now
Read now
Wenjie Zeng, Lars L Gustafsson, Marion Bennie, Alexander E Finlayson & Brian Godman. (2015) Review of ongoing initiatives to improve prescribing efficiency in China; angiotensin receptor blockers as a case history. Expert Review of Pharmacoeconomics & Outcomes Research 15:1, pages 157-169.
Read now
Read now
Cecilia Lenander, Birgitta Elfsson, Birgitta Danielsson, Patrik Midlöv & Jan Hasselström. (2014) Effects of a pharmacist-led structured medication review in primary care on drug-related problems and hospital admission rates: a randomized controlled trial. Scandinavian Journal of Primary Health Care 32:4, pages 180-186.
Read now
Read now
Brian Godman, Iain Bishop, Alexander E Finlayson, Stephen Campbell, Hye-Young Kwon & Marion Bennie. (2013) Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries. Expert Review of Pharmacoeconomics & Outcomes Research 13:4, pages 469-482.
Read now
Read now
Jessica Fraeyman, Guido Van Hal, Brian Godman & Philippe Beutels. (2013) The potential influence of various initiatives to improve rational prescribing for proton pump inhibitors and statins in Belgium. Expert Review of Pharmacoeconomics & Outcomes Research 13:1, pages 141-151.
Read now
Read now
Pieter Dylst, Arnold Vulto & Steven Simoens. (2013) Demand-side policies to encourage the use of generic medicines: an overview. Expert Review of Pharmacoeconomics & Outcomes Research 13:1, pages 59-72.
Read now
Read now
Anna Bucsics, Brian Godman, Thomas Burkhardt, Manuela Schmitzer & Rickard E Malmström. (2012) Influence of lifting prescribing restrictions for losartan on subsequent sartan utilization patterns in Austria: implications for other countries. Expert Review of Pharmacoeconomics & Outcomes Research 12:6, pages 809-819.
Read now
Read now
Mohammed Abuelkhair, Shajahan Abdu, Brian Godman, Sahar Fahmy, Rickard E Malmström & Lars L Gustafsson. (2012) Imperative to consider multiple initiatives to maximize prescribing efficiency from generic availability: case history from Abu Dhabi. Expert Review of Pharmacoeconomics & Outcomes Research 12:1, pages 115-124.
Read now
Read now
Luka Vončina, Tihomir Strizrep, Brian Godman, Marion Bennie, Iain Bishop, Stephen Campbell, Vera Vlahović-Palčevski & Lars L Gustafsson. (2011) Influence of demand-side measures to enhance renin–angiotensin prescribing efficiency in Europe: implications for the future. Expert Review of Pharmacoeconomics & Outcomes Research 11:4, pages 469-479.
Read now
Read now
Kristina Garuoliene, Brian Godman, Jolanta Gulbinovič, Björn Wettermark & Alan Haycox. (2011) European countries with small populations can obtain low prices for drugs: Lithuania as a case history. Expert Review of Pharmacoeconomics & Outcomes Research 11:3, pages 343-349.
Read now
Read now
Brian Godman, Solveig Sakshaug, Christian Berg, Björn Wettermark & Alan Haycox. (2011) Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs. Expert Review of Pharmacoeconomics & Outcomes Research 11:1, pages 121-129.
Read now
Read now
Brian Godman, William Shrank, Morten Andersen, Christian Berg, Iain Bishop, Thomas Burkhardt, Kristina Garuoliene, Harald Herholz, Roberta Joppi, Marija Kalaba, Ott Laius, Diane McGinn, Vita Samaluk, Catherine Sermet, Ulrich Schwabe, Inês Teixeira, Lesley Tilson, F Cankat Tulunay, Vera Vlahović-Palčevski, Kamila Wendykowska, Björn Wettermark, Corinne Zara & Lars L Gustafsson. (2010) Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications. Expert Review of Pharmacoeconomics & Outcomes Research 10:6, pages 707-722.
Read now
Read now
Brian Godman, Anna Bucsics, Thomas Burkhardt, Manuela Schmitzer, Björn Wettermark & Peter Wieninger. (2010) Initiatives to enhance renin–angiotensin prescribing efficiency in Austria: impact and implications for other countries. Expert Review of Pharmacoeconomics & Outcomes Research 10:2, pages 199-207.
Read now
Read now
Diane McGinn, Brian Godman, Julie Lonsdale, Rosalind Way, Björn Wettermark & Alan Haycox. (2010) Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implications. Expert Review of Pharmacoeconomics & Outcomes Research 10:1, pages 73-85.
Read now
Read now
Anna Coma, Corinne Zara, Brian Godman, Antònia Agustí, Eduardo Diogène, Björn Wettermark & Alan Haycox. (2009) Policies to enhance the efficiency of prescribing in the Spanish Catalan region: impact and future direction. Expert Review of Pharmacoeconomics & Outcomes Research 9:6, pages 569-581.
Read now
Read now
Brian Godman, Thomas Burkhardt, Anna Bucsics, Björn Wettermark & Peter Wieninger. (2009) Impact of recent reforms in Austria on utilization and expenditure of PPIs and lipid-lowering drugs: implications for the future. Expert Review of Pharmacoeconomics & Outcomes Research 9:5, pages 475-484.
Read now
Read now
Articles from other publishers (79)
Elkanah Linder, Björn Wettermark, Marie-Louise Ovesjö, Sofia Kälvemark Sporrong & Helena Ramström. (2023) Knowledge support for environmental information on pharmaceuticals: experiences among Swedish Drug and Therapeutics Committees. BMC Health Services Research 23:1.
Crossref
Crossref
Georges Hatem, Elsa LahoudLeyan Halwani, Farah McheikDalia KhachmanSanaa Awada. (2022) The unified medical prescription as a tool to promote generic prescription: A cross-sectional study addressing physicians’ perception in Lebanon. Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector 18:4, pages 214-222.
Crossref
Crossref
Johanna C Meyer, Sean MacBride-Stewart, Joseph O Fadare, Ammar Abdulrahman Jairoun, Mainul Haque, Amos Massele, Santosh Kumar, Israel Abebrese Sefah, Phumzile P Skosana & Brian Godman. (2022) Key Considerations From a Health Authority Perspective When Proton Pump Inhibitors Are Used to Treat Gastroesophageal Reflux Disease (GERD) and Their Implications. Cureus.
Crossref
Crossref
Sinenhlanhla Pearl Guma, Brian Godman, Stephen M. Campbell & Ozayr Mahomed. (2022) Determinants of the Empiric Use of Antibiotics by General Practitioners in South Africa: Observational, Analytic, Cross-Sectional Study. Antibiotics 11:10, pages 1423.
Crossref
Crossref
Magdalena Zielińska & Tomasz Hermanowski. (2022) Sources of Information on Medicinal Products Among Physicians – A Survey Conducted Among Primary Care Physicians in Poland. Frontiers in Pharmacology 12.
Crossref
Crossref
Mingyue Zhao, Peng Nie & Jing Wu. (2021) Heterogeneity in Price Elasticity of Medicine Demand in China: Moderate Effect From Economic Incentive and Quality Difference. Frontiers in Pharmacology 12.
Crossref
Crossref
Brian Godman, Joseph Fadare, Hye-Young Kwon, Carolina Zampirolli Dias, Amanj Kurdi, Isabella Piassi Dias Godói, Dan Kibuule, Iris Hoxha, Sylvia Opanga, Zikria Saleem, Tomasz Bochenek, Vanda Marković-Peković, Ileana Mardare, Aubrey C Kalungia, Stephen Campbell, Eleonora Allocati, Alice Pisana, Antony P Martin & Johanna C Meyer. (2021) Evidence-based public policy making for medicines across countries: findings and implications for the future. Journal of Comparative Effectiveness Research 10:12, pages 1019-1052.
Crossref
Crossref
Habtamu Seyoum, Zinabie Feleke, Dinkineh Bikila, Alebel Yaregal, Amsalu Demisie, Seid Ali, Salem Fisseha, Yigeremu Abebe, Audrey Battu, Felix Lam & Regasa Bayisa. (2023) Drug and Therapeutics Committee (DTC) evolvement and expanded scope in Ethiopia. Gates Open Research 5, pages 70.
Crossref
Crossref
Love Linnér, Irene Eriksson, Marie Persson & Björn Wettermark. (2020) Forecasting drug utilization and expenditure: ten years of experience in Stockholm. BMC Health Services Research 20:1.
Crossref
Crossref
Amanj Kurdi, Rachel Ann Elliott & Li-Chia Chen. (2020) Lessons from the failure of implementing the ‘Better Care Better Value’ prescribing indicator for renin–angiotensin system drugs in England: a qualitative study of general practitioners’ perceptions using behavioural change framework. BMJ Open 10:6, pages e035910.
Crossref
Crossref
Marina Morgado Garcia, Pamela Santos Azevedo, Andrew Mirelman, Leandro Pinheiro Safatle, Roberto Iunes, Marion Clark Bennie, Brian Godman & Augusto Afonso Guerra Junior. (2020) Funding and Service Organization to Achieve Universal Health Coverage for Medicines: An Economic Evaluation of the Best Investment and Service Organization for the Brazilian Scenario.. Frontiers in Pharmacology 11.
Crossref
Crossref
Mohamed Gad, Ahmed Salem, Wija Oortwijn, Ruaraidh Hill & Brian Godman. (2020) Mapping of Current Obstacles for Rationalizing Use of Medicines (CORUM) in Europe: Current Situation and Potential Solutions. Frontiers in Pharmacology 11.
Crossref
Crossref
Brian Godman. (2020) Ongoing initiatives to improve the prescribing of medicines across sectors and the implications. Advances in Human Biology 10:3, pages 85.
Crossref
Crossref
Samar F. Farid. (2019) Conceptual Framework of the Impact of Health Technology on Healthcare System. Frontiers in Pharmacology 10.
Crossref
Crossref
Brian Godman, Amanj Kurdi, Holly McCabe, Chris F Johnson, Corrado Barbui, Sean MacBride-Stewart, Simon Hurding, Axel Leporowski, Marion Bennie & Alec Morton. (2019) Ongoing initiatives within the Scottish National Health Service to affect the prescribing of selective serotonin reuptake inhibitors and their influence. Journal of Comparative Effectiveness Research 8:7, pages 535-547.
Crossref
Crossref
Brian Godman, Anna Bucsics, Patricia Vella Bonanno, Wija Oortwijn, Celia C. Rothe, Alessandra Ferrario, Simone Bosselli, Andrew Hill, Antony P. Martin, Steven Simoens, Amanj Kurdi, Mohamed Gad, Jolanta Gulbinovič, Angela Timoney, Tomasz Bochenek, Ahmed Salem, Iris Hoxha, Robert Sauermann, Amos Massele, Augusto Alfonso GuerraJr.Jr., Guenka Petrova, Zornitsa Mitkova, Gnosia Achniotou, Ott Laius, Catherine Sermet, Gisbert Selke, Vasileios Kourafalos, John Yfantopoulos, Einar Magnusson, Roberta Joppi, Margaret Oluka, Hye-Young Kwon, Arianit Jakupi, Francis Kalemeera, Joseph O. Fadare, Oyvind Melien, Maciej Pomorski, Magdalene Wladysiuk, Vanda Marković-Peković, Ileana Mardare, Dmitry Meshkov, Tanja Novakovic, Jurij Fürst, Dominik Tomek, Corrine Zara, Eduardo Diogene, Johanna C. Meyer, Rickard Malmström, Björn Wettermark, Zinhle Matsebula, Stephen Campbell & Alan Haycox. (2018) Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets. Frontiers in Public Health 6.
Crossref
Crossref
Hye-Young Kwon, Hyungmin Kim & Brian Godman. (2018) Availability and Affordability of Drugs With a Conditional Approval by the European Medicines Agency; Comparison of Korea With Other Countries and the Implications. Frontiers in Pharmacology 9.
Crossref
Crossref
Seda Kumru & Mehmet Top. (2018) Pricing and reimbursement of generic pharmaceuticals in Turkey: Evaluation of hypertension drugs from 2007 to 2013. Health Policy and Technology 7:2, pages 182-193.
Crossref
Crossref
Ljubica Bojanić, Vanda Marković-Peković, Ranko Škrbić, Nataša Stojaković, Mirjana Ðermanović, Janja Bojanić, Jurij Fürst, Amanj B. Kurdi & Brian Godman. (2018) Recent Initiatives in the Republic of Srpska to Enhance Appropriate Use of Antibiotics in Ambulatory Care; Their Influence and Implications. Frontiers in Pharmacology 9.
Crossref
Crossref
Claudia G. S. Osorio-de-Castro, Thiago B. Azeredo, Vera L. E. Pepe, Luciane C. Lopes, Sueli Yamauti, Brian Godman & Lars L. Gustafsson. (2018) Policy Change and the National Essential Medicines List Development Process in Brazil between 2000 and 2014: Has the Essential Medicine Concept been Abandoned?. Basic & Clinical Pharmacology & Toxicology 122:4, pages 402-412.
Crossref
Crossref
Jaran Eriksen, Marie-Louise Ovesjö, Martina Vallin, Maria Juhasz-Haverinen, Eva Andersén-Karlsson, Kristina Ateva, Lars L Gustafsson, Malena Jirlow & Pia Bastholm-Rahmner. (2017) Primary care physicians report high trust in and usefulness of the Stockholm drug and therapeutic committee’s list of recommended essential medicines (the ‘Wise List’). European Journal of Clinical Pharmacology 74:1, pages 131-138.
Crossref
Crossref
Fadi El-Jardali, Racha Fadlallah, Rami Z. Morsi, Nour Hemadi, Mounir Al-Gibbawi, Magda Haj, Suzan Khalil, Youssef Saklawi, Diana Jamal & Elie A. Akl. (2017) Pharmacists’ views and reported practices in relation to a new generic drug substitution policy in Lebanon: a mixed methods study. Implementation Science 12:1.
Crossref
Crossref
Velisha Ann Perumal-Pillay & Fatima Suleman. (2017) Parents’ and guardians’ perceptions on availability and pricing of medicines and healthcare for children in eThekwini, South Africa – a qualitative study. BMC Health Services Research 17:1.
Crossref
Crossref
Irene Eriksson, Björn Wettermark, Marie Persson, Morgan Edström, Brian Godman, Anna Lindhé, Rickard E. Malmström, Helena Ramström, Mia von Euler & Anna Bergkvist Christensen. (2017) The Early Awareness and Alert System in Sweden: History and Current Status. Frontiers in Pharmacology 8.
Crossref
Crossref
Hye-Young Kwon & Brian Godman. (2017) Drug Pricing in South Korea. Applied Health Economics and Health Policy 15:4, pages 447-453.
Crossref
Crossref
Jaran Eriksen, Lars L Gustafsson, Kristina Ateva, Pia Bastholm-Rahmner, Marie-Louise Ovesjö, Malena Jirlow, Maria Juhasz-Haverinen, Gerd Lärfars, Rickard E Malmström, Björn Wettermark & Eva Andersén-Karlsson. (2017) High adherence to the ‘Wise List’ treatment recommendations in Stockholm: a 15-year retrospective review of a multifaceted approach promoting rational use of medicines. BMJ Open 7:4, pages e014345.
Crossref
Crossref
Hye-Young Kwon & Brian Godman. (2016) Do newly marketed generic medicines expand markets using descriptive time series analysis and mixed logit models? Korea as an exemplar and its implications. BMC Health Services Research 16:1.
Crossref
Crossref
Sabine Vogler, Nina Zimmermann & Kees de Joncheere. (2016) Policy interventions related to medicines: Survey of measures taken in European countries during 2010–2015. Health Policy 120:12, pages 1363-1377.
Crossref
Crossref
Shinobu Imai, Karolina Andersson Sundell & Kiyohide Fushimi. (2016) Comparison of pharmaceutical policies to stimulate use of generics in Japan and Sweden. Health Policy and Technology 5:2, pages 189-195.
Crossref
Crossref
Onyinye Onyeka Akunne, Brian Godman, Aduragbenro Deborah Adedapo, Ilse Truter & Joseph Fadare. (2016) Statin prescribing among hypertensive patients in southwest Nigeria: findings and implications for the future. Journal of Comparative Effectiveness Research 5:3, pages 281-288.
Crossref
Crossref
Elisabetta Poluzzi, Giacomo Veronese, Carlo Piccinni, Emanuel Raschi, Ariola Koci, Paola Pagano, Brian Godman, Giulio Marchesini, Giuseppe Boriani & Fabrizio De Ponti. (2016) Switching among Equivalents in Chronic Cardiovascular Therapies: ‘Real World’ Data from Italy. Basic & Clinical Pharmacology & Toxicology 118:1, pages 63-69.
Crossref
Crossref
Wenjie Zeng, Alexander E Finlayson, Sushma Shankar, Winnie de Bruyn & Brian Godman. (2015) Prescribing efficiency of proton pump inhibitors in China: influence and future directions. BMC Health Services Research 15:1.
Crossref
Crossref
Amanj Baker, Li-Chia Chen, Rachel A. Elliott & Brian Godman. (2015) The impact of the ‘Better Care Better Value’ prescribing policy on the utilisation of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for treating hypertension in the UK primary care setting: longitudinal quasi-experimental design. BMC Health Services Research 15:1.
Crossref
Crossref
Humayun Riaz, Brian Godman, Shahzad Hussain, Farnaz Malik, Sidra Mahmood, Ali Shami & Sajid Bashir. (2015) Prescribing of bisphosphonates and antibiotics in Pakistan: challenges and opportunities for the future. Journal of Pharmaceutical Health Services Research 6:2, pages 111-121.
Crossref
Crossref
Hye-Young Kwon, Bongmin Yang & Brian Godman. (2015) Key Components of Increased Drug Expenditure in South Korea: Implications for the Future. Value in Health Regional Issues 6, pages 14-21.
Crossref
Crossref
Ilse Truter, Sushma Shankar, Marion Bennie, Menno van Woerkom & Brian Godman. (2015) Initiatives in South Africa to enhance the prescribing of generic proton pump inhibitors: findings and implications. Journal of Comparative Effectiveness Research 4:2, pages 123-131.
Crossref
Crossref
Helle Håkonsen & Karolina Andersson Sundell. 2015. Pharmaceutical Prices in the 21st Century. Pharmaceutical Prices in the 21st Century
209
227
.
Therese Kardakis, Göran Tomson, Björn Wettermark, Mats Brommels, Brian Godman & Pia Bastholm-Rahmner. (2015) The establishment and expansion of an innovative centre for rational pharmacotherapy-determinants and challenges. The International Journal of Health Planning and Management 30:1, pages 14-30.
Crossref
Crossref
Veronica Milos, Tommy Westerlund, Patrik Midlöv & Eva Lena Strandberg. (2014) Swedish general practitioners’ attitudes towards treatment guidelines – a qualitative study. BMC Family Practice 15:1.
Crossref
Crossref
Brian Godman, Max Petzold, Kathleen Bennett, Marion Bennie, Anna Bucsics, Alexander E Finlayson, Andrew Martin, Marie Persson, Jutta Piessnegger, Emanuel Raschi, Steven Simoens, Corinne Zara & Corrado Barbui. (2014) Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications. BMC Medicine 12:1.
Crossref
Crossref
Mohamed Azmi Hassali, Alian A. Alrasheedy, Andrew McLachlan, Tuan Anh Nguyen, Saleh Karamah AL-Tamimi, Mohamed Izham Mohamed Ibrahim & Hisham Aljadhey. (2014) The experiences of implementing generic medicine policy in eight countries: A review and recommendations for a successful promotion of generic medicine use. Saudi Pharmaceutical Journal 22:6, pages 491-503.
Crossref
Crossref
James C. Moon, Brian Godman, Max Petzold, Samantha Alvarez-Madrazo, Kathleen Bennett, Iain Bishop, Anna Bucsics, Ulrik Hesse, Andrew Martin, Steven Simoens, Corinne Zara & Rickard E. Malmström. (2014) Different initiatives across Europe to enhance losartan utilization post generics: impact and implications. Frontiers in Pharmacology 5.
Crossref
Crossref
Elisangela da Costa Lima-Dellamora, Rosângela Caetano, Lars L. Gustafsson, Brian B. Godman, Ken Patterson & Claudia Garcia Serpa Osorio-de-Castro. (2014) An Analytical Framework for Assessing Drug and Therapeutics Committee Structure and Work Processes in Tertiary Brazilian Hospitals. Basic & Clinical Pharmacology & Toxicology 115:3, pages 268-276.
Crossref
Crossref
Wenjie Zeng, Junjie Zhen, Mengying Feng, Stephen M Campbell, Alexander E Finlayson & Brian Godman. (2014) Analysis of the influence of recent reforms in China: cardiovascular and cerebrovascular medicines as a case history to provide future direction. Journal of Comparative Effectiveness Research 3:4, pages 371-386.
Crossref
Crossref
R. Fernández Urrusuno, P. Pérez Pérez, M. C. Montero Balosa, C. Márquez Calzada & B. Pascual de la Pisa. (2013) Compliance with quality prescribing indicators linked to financial incentives: what about not incentivized indicators?: an observational study. European Journal of Clinical Pharmacology 70:3, pages 303-311.
Crossref
Crossref
Ana Luísa Caires de Souza, Francisco de Assis Acurcio, Augusto Afonso Guerra Júnior, Renata Cristina Rezende Macedo do Nascimento, Brian Godman & Leonardo Maurício Diniz. (2014) Insulin Glargine in a Brazilian State: Should the Government Disinvest? An Assessment Based on a Systematic Review. Applied Health Economics and Health Policy 12:1, pages 19-32.
Crossref
Crossref
Andrew Martin, Brian GodmanJamilette Miranda, Jeanette Tilstone, Nigget Saleem, Erika Olsson, Angela Acosta, Luis Restrepo & Marion Bennie. (2014) Measures to improve angiotensin receptor blocker prescribing efficiency in the UK: findings and implications. Journal of Comparative Effectiveness Research 3:1, pages 41-51.
Crossref
Crossref
Brian Godman, Alexander E Finlayson, Parneet K Cheema, Eva Zebedin-Brandl, Inaki Gutiérrez-Ibarluzea, Jan Jones, Rickard E Malmström, Elina Asola, Christoph Baumgärtel, Marion Bennie, Iain Bishop, Anna Bucsics, Stephen Campbell, Eduardo Diogene, Alessandra Ferrario, Jurij Fürst, Kristina Garuoliene, Miguel Gomes, Katharine Harris, Alan Haycox, Harald Herholz, Krystyna Hviding, Saira Jan, Marija Kalaba, Christina Kvalheim, Ott Laius, Sven-Ake Lööv, Kamila Malinowska, Andrew Martin, Laura McCullagh, Fredrik Nilsson, Ken Paterson, Ulrich Schwabe, Gisbert Selke, Catherine Sermet, Steven Simoens, Dominik Tomek, Vera Vlahovic-Palcevski, Luka Voncina, Magdalena Wladysiuk, Menno van Woerkom, Durhane Wong-Rieger, Corrine Zara, Raghib Ali & Lars L Gustafsson. (2013) Personalizing health care: feasibility and future implications. BMC Medicine 11:1.
Crossref
Crossref
Ulrik Hesse, Brian Godman, Max Petzold, Andrew Martin & Rickard E. Malmström. (2013) Impact of Delisting ARBs, Apart from Losartan, on ARB Utilisation Patterns in Denmark: Implications for Other Countries. Applied Health Economics and Health Policy 11:6, pages 677-685.
Crossref
Crossref
Brian Godman, Kristien De Bruyn, Jamilette Miranda, Emanuel Raschi, Marion Bennie, Corrado Barbui & Steven Simoens. (2013) Generic atypical antipsychotic drugs in Belgium: their influence and implications. Journal of Comparative Effectiveness Research 2:6, pages 551-561.
Crossref
Crossref
Pieter Dylst, Arnold Vulto, Brian Godman & Steven Simoens. (2013) Generic Medicines: Solutions for a Sustainable Drug Market?. Applied Health Economics and Health Policy 11:5, pages 437-443.
Crossref
Crossref
Brian Godman, Marie Persson, Jamilette Miranda, Corrado Barbui, Marion Bennie, Alexander E Finlayson, Emanuel Raschi & Bjorn Wettermark. (2013) Can authorities take advantage of the availability of generic atypical antipsychotic drugs? Findings from Sweden and potential implications. Journal of Pharmaceutical Health Services Research 4:3, pages 139-150.
Crossref
Crossref
Steven Simoens, Kristien De Bruyn, Jamilette Miranda, Marion Bennie, Rickard E. Malmström & Brian Godman. (2013) Measures to enhance angiotensin-receptor blocker prescribing efficiency in Belgium following generic losartan: impact and implications for the future. Journal of Pharmaceutical Health Services Research 4:3, pages 173-181.
Crossref
Crossref
B. Godman, B. Wettermark, J. Miranda, M. Bennie, A. Martin & R. E. Malmström. (2013) Influence of multiple initiatives in Sweden to enhance ARB prescribing efficiency following generic losartan; findings and implications for other countries. International Journal of Clinical Practice 67:9, pages 853-862.
Crossref
Crossref
Brian Godman, Marie Persson, Jamilette Miranda, Peter Skiöld, Björn Wettermark, Corrado Barbui & Lars L. Gustafsson. (2013) Changes in the Utilization of Venlafaxine after the Introduction of Generics in Sweden. Applied Health Economics and Health Policy 11:4, pages 383-393.
Crossref
Crossref
Su-Yeon Yu, Bong-Min Yang & Jin-Hyun Kim. (2013) New Anti-Rebate Legislation in South Korea. Applied Health Economics and Health Policy 11:4, pages 311-318.
Crossref
Crossref
Thomas Cars, Björn Wettermark, Rickard E. Malmström, Gunnar Ekeving, Bo Vikström, Ulf Bergman, Martin Neovius, Bo Ringertz & Lars L. Gustafsson. (2013)
Extraction of Electronic Health Record Data in a Hospital Setting: Comparison of Automatic and Semi‐Automatic Methods Using Anti‐
TNF
Therapy as Model
. Basic & Clinical Pharmacology & Toxicology 112:6, pages 392-400.
Crossref
Crossref
Sylvain Pichetti, Catherine Sermet, Brian Godman, Stephen M. Campbell & Lars L. Gustafsson. (2013) Multilevel Analysis of the Influence of Patients’ and General Practitioners’ Characteristics on Patented Versus Multiple-Sourced Statin Prescribing in France. Applied Health Economics and Health Policy 11:3, pages 205-218.
Crossref
Crossref
Mikael Hoffmann. (2013) The right drug, but from whose perspective? A framework for analysing the structure and activities of drug and therapeutics committees. European Journal of Clinical Pharmacology 69:S1, pages 79-87.
Crossref
Crossref
Gunnar Alván, Marine L. Andersson, Annika B. Asplund, Ylva Böttiger, Carl-Eric Elwin, Lars L. Gustafsson, Birgitta Öhman & Elisabeth Törnqvist. (2013) The continuing challenge of providing drug information services to diminish the knowledge—practice gap in medical practice. European Journal of Clinical Pharmacology 69:S1, pages 65-72.
Crossref
Crossref
Ulrika Nörby, Karin Källén, Birgit Eiermann, Seher Korkmaz, Birger Winbladh & Lars L. Gustafsson. (2012) Drugs and Birth Defects: a knowledge database providing risk assessments based on national health registers. European Journal of Clinical Pharmacology 69:4, pages 889-899.
Crossref
Crossref
A E Finlayson, B Godman, K Paterson, E Aston, A Haycox, Ll Gustafsson & R Ali. (2013) Personalizing healthcare: from genetics through payment to improving care?. Journal of the Royal Society of Medicine 106:2, pages 41-44.
Crossref
Crossref
Brian Godman & Lars L. Gustafsson. (2013) A New Reimbursement System for Innovative Pharmaceuticals Combining Value-Based and Free Market Pricing. Applied Health Economics and Health Policy 11:1, pages 79-82.
Crossref
Crossref
Caitriona Cahir, Tom Fahey, Lesley Tilson, Conor Teljeur & Kathleen Bennett. (2012) Proton pump inhibitors: potential cost reductions by applying prescribing guidelines. BMC Health Services Research 12:1.
Crossref
Crossref
Menno van Woerkom, Hans Piepenbrink, Brian GodmanJoost de Metz, Stephen Campbell, Marion Bennie, Marietta Eimers & Lars L Gustafsson. (2012) Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications. Journal of Comparative Effectiveness Research 1:6, pages 527-538.
Crossref
Crossref
Billie Pettersson, Mikael Hoffmann, Per Wändell & Lars-Åke Levin. (2012) Utilization and costs of lipid modifying therapies following health technology assessment for the new reimbursement scheme in Sweden. Health Policy 104:1, pages 84-91.
Crossref
Crossref
Lars L. Gustafsson, Björn Wettermark, Brian Godman, Eva Andersén-Karlsson, Ulf Bergman, Jan Hasselström, Lars-Olof Hensjö, Paul Hjemdahl, Ingrid Jägre, Margaretha Julander, Bo Ringertz, Daniel Schmidt, Susan Sjöberg, Folke Sjöqvist, Carl-Olav Stiller, Elisabeth Törnqvist, Rolf Tryselius, Sigurd Vitols & Christer von Bahr. (2011) The ‘Wise List’- A Comprehensive Concept to Select, Communicate and Achieve Adherence to Recommendations of Essential Drugs in Ambulatory Care in Stockholm. Basic & Clinical Pharmacology & Toxicology 108:4, pages 224-233.
Crossref
Crossref
Jakub Adamski, Brian Godman, Gabriella Ofierska-Sujkowska, Bogusława Osińska, Harald Herholz, Kamila Wendykowska, Ott Laius, Saira Jan, Catherine Sermet, Corrine Zara, Marija Kalaba, Roland Gustafsson, Kristina Garuolienè, Alan Haycox, Silvio Garattini & Lars L Gustafsson. (2010) Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC Health Services Research 10:1.
Crossref
Crossref
Björn Wettermark, Marie E Persson, Nils Wilking, Mats Kalin, Seher Korkmaz, Paul Hjemdahl, Brian Godman, Max Petzold & Lars L Gustafsson. (2010) Forecasting drug utilization and expenditure in a metropolitan health region. BMC Health Services Research 10:1.
Crossref
Crossref
Brian Godman, William Shrank, Bjorn Wettermark, Morten Andersen, Iain Bishop, Thomas Burkhardt, Kristina Garuolienè, Marija Kalaba, Ott Laius, Roberta Joppi, Catherine Sermet, Ulrich Schwabe, Inês Teixeira, F. Cankat Tulunay, Kamila Wendykowska, Corinne Zara & Lars L Gustafsson. (2010) Use of Generics—A Critical Cost Containment Measure for All Healthcare Professionals in Europe?. Pharmaceuticals 3:8, pages 2470-2494.
Crossref
Crossref
Michael Orme, Folke Sjöqvist, Donald Birkett, Kim Brøsen, Ingolf Cascorbi, Lars L Gustafsson, Simon Maxwell, Lembit Rago, Michael Rawlins, Marcus Reidenberg, Folke Sjöqvist, Tony Smith, Petra Thuerman & Andrew Walubo. (2010) Clinical Pharmacology in Research, Teaching and Health Care. Basic & Clinical Pharmacology & Toxicology 107:1, pages 531-559.
Crossref
Crossref
Jaume Puig-Junoy. (2010) Políticas de fomento de la competencia en precios en el mercado de genéricos: lecciones de la experiencia europea. Gaceta Sanitaria 24:3, pages 193-199.
Crossref
Crossref
Björn Wettermark, Brian Godman, Martin Neovius, Niklas Hedberg, Tor-Olov Mellgren & Thomas Kahan. (2010) Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment. Health Policy 94:3, pages 221-229.
Crossref
Crossref
Racheli Magnezi, Lilach Elzam, Yaniv Kliker, Ron Kedem, Gil Fire & Rachel Wilf-Miron. (2010) Cost awareness when prescribing treatment. British Journal of Healthcare Management 16:2, pages 62-72.
Crossref
Crossref
Marianne Heibert Arnlind, Björn Wettermark, Mika Nokela, Paul Hjemdahl, Clas Rehnberg & Eva Wikström Jonsson. (2009) Regional variation and adherence to guidelines for drug treatment of asthma. European Journal of Clinical Pharmacology 66:2, pages 187-198.
Crossref
Crossref
Catherine Sermet, Veronique Andrieu, Brian Godman, Eric Van Ganse, Alan Haycox & Jean-Pierre Reynier. (2012) Ongoing pharmaceutical reforms in France. Applied Health Economics and Health Policy 8:1, pages 7-24.
Crossref
Crossref
C. Norman, R. Zarrinkoub, J. Hasselström, B. Godman, F. Granath & B. Wettermark. (2009) Potential savings without compromising the quality of care. International Journal of Clinical Practice 63:9, pages 1320-1326.
Crossref
Crossref
Björn Wettermark, Brian Godman, Bengt Jacobsson & Flora M. Haaijer-Ruskamp. (2012) Soft regulations in pharmaceutical policy making. Applied Health Economics and Health Policy 7:3, pages 137-147.
Crossref
Crossref
Brian Godman, Ulrich Schwabe, Gisbert Selke & Björn Wettermark. (2009) Update of Recent Reforms in Germany to Enhance the Quality and Efficiency of Prescribing of Proton Pump Inhibitors and Lipid-Lowering Drugs. PharmacoEconomics 27:5, pages 435-438.
Crossref
Crossref